Expression and characterization of recombinant IL-1Ra in Aspergillus oryzae as a system

Expression and characterization of recombinant IL-1Ra in Aspergillus oryzae as a system

Abstract Background The interleukin-1 receptor antagonist (IL-1Ra) is a crucial molecule that counteracts the effects of interleukin-1 (IL-1) by binding to its receptor. A high concentration of IL-1Ra is required for complete inhibition of IL-1 activity. However, the currently available Escherichia...

Full description

Bibliographic Details
Main Authors:	Lena Mahmoudi Azar, Elif Karaman, Burcu Beyaz, Işılay Göktan, Alp Ertunga Eyüpoğlu, Seda Kizilel, Batu Erman, Ahmet Gül, Serdar Uysal
Format:	Article
Language:	English
Published:	BMC 2023-06-01
Series:	BMC Biotechnology
Subjects:	Interleukin-1 receptor antagonist Anakinra IL-1Ra Half-life Aspergillus oryzae Surface plasmon resonance
Online Access:	https://doi.org/10.1186/s12896-023-00785-7

Similar Items

Large-Scale Production of Anti-RNase A VHH Expressed in <i>pyrG</i> Auxotrophic <i>Aspergillus oryzae</i>
by: Elif Karaman, et al.
Published: (2023-05-01)

Recombinant Production and One Step Purification of IL-1Ra in Escherichia coli and Evaluation its IL-1 Antagonizing Efficacy
by: Roya Adelnia, et al.
Published: (2021-06-01)

Defective Glyoxalase 1 Contributes to Pathogenic Inflammation in Cystic Fibrosis
by: Marilena Pariano, et al.
Published: (2021-11-01)

Human ACE2 orthologous peptide sequences show better binding affinity to SARS-CoV-2 RBD domain: Implications for drug design
by: Lena Mahmoudi Azar, et al.
Published: (2023-01-01)

The IL-1 Antagonist Anakinra Attenuates Glioblastoma Aggressiveness by Dampening Tumor-Associated Inflammation
by: Max Hübner, et al.
Published: (2020-02-01)

Use of Anakinra in steroid dependent recurrent pericarditis: a case report and review of literature
by: Vinay Kumar Thallapally, et al.
Published: (2021-07-01)

Population Structure of Double-Stranded RNA Mycoviruses That Infect the Rice Blast Fungus Magnaporthe oryzae in Japan
by: Yuta Owashi, et al.
Published: (2020-10-01)

Efficacy of Anakinra on Multiple Coronary Arteries Aneurysms in an Infant with Recurrent Kawasaki Disease, Complicated by Macrophage Activation Syndrome
by: Grazia Bossi, et al.
Published: (2022-05-01)

Systematic Review of Safety and Efficacy of IL-1-Targeted Biologics in Treating Immune-Mediated Disorders
by: Dennis D. Arnold, et al.
Published: (2022-07-01)

Use of anakinra in severe COVID-19: A case report
by: Giovanni Filocamo, et al.
Published: (2020-07-01)

IL-1 Inhibitors in the Treatment of Monogenic Periodic Fever Syndromes: From the Past to the Future Perspectives
by: Hana Malcova, et al.
Published: (2021-02-01)

Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma
by: Madelyn Espinosa-Cotton, et al.
Published: (2019-03-01)

Comparison of Tocilizumab and Anakinra in the Treatment of COVID-19: A Single-Center Experience
by: Bengisu Pınar Acat, et al.
Published: (2022-08-01)

Application of anakinra in inflammatory dermatoses
by: Xiaomei YOU, et al.
Published: (2024-01-01)

Erratum in: Budget Impact Analysis of anakinra in the treatment of patients with Still’s Disease
by: Roberto Ravasio, et al.
Published: (2020-09-01)

Long-term control of refractory Schnitzler syndrome with anakinra: a case report
by: Hsien-Yi Chiu, et al.
Published: (2010-06-01)

Deepwater response in the African cultivated rice Oryza glaberrima
by: Quanshu Luo, et al.
Published: (2023-01-01)

A Systematic Review of the Safety of Blocking the IL-1 System in Human Pregnancy
by: Marie-Eve Brien, et al.
Published: (2021-12-01)

The role of interleukin 1 in the development of human diseases: focus on Anakinra (IL-1 receptor antagonist)
by: E. L. Nasonov, et al.
Published: (2022-07-01)

Off-Label studies on anakinra in dermatology: a review
by: Kyle Tegtmeyer, et al.
Published: (2022-01-01)

A snapshot on the on-label and off-label use of the interleukin-1 inhibitors in Italy among rheumatologists and pediatric rheumatologists: a nationwide multi-center retrospective observational study
by: Antonio Vitale, et al.
Published: (2016-10-01)

Effects of interleukin-1 antagonism on cortisol levels in individuals with obesity: a randomized clinical trial
by: Fahim Ebrahimi, et al.
Published: (2019-05-01)

Rationale and design of interleukin-1 blockade in recently decompensated heart failure (REDHART2): a randomized, double blind, placebo controlled, single center, phase 2 study
by: Benjamin Van Tassell, et al.
Published: (2022-06-01)

Failure of anti Interleukin-1 β monoclonal antibody in the treatment of recurrent pericarditis in two children
by: Sara Signa, et al.
Published: (2020-06-01)

Hrip1 mediates rice cell wall fortification and phytoalexins elicitation to confer immunity against Magnaporthe oryzae
by: Vincent Ninkuu, et al.
Published: (2022-09-01)

Mutagenesis of PhaR, a Regulator Gene of Polyhydroxyalkanoate Biosynthesis of Xanthomonas oryzae pv. oryzae Caused Pleiotropic Phenotype Changes
by: Ju-Ying Long, et al.
Published: (2018-12-01)

Pest categorisation of Xanthomonas oryzae pathovars oryzae and oryzicola
by: EFSA Panel on Plant Health (PLH), et al.
Published: (2018-01-01)

The Beneficial Outcome of Subsequent Treatment with Anakinra during the Chronic Phase of Febrile Infection-Related Epilepsy Syndrome (FIRES): A Case Report
by: Tina Luize Cupane, et al.
Published: (2023-12-01)

Differential Response to Interleukin‐1 Blockade With Anakinra on Cardiorespiratory Fitness in Patients With Heart Failure With Preserved Ejection Fraction Stratified According to Left Ventricular Ejection Fraction
by: Michele Golino, et al.
Published: (2023-09-01)

Do Interleukin-1 and Interleukin-6 Antagonists Hold Any Place in the Treatment of Atherosclerotic Cardiovascular Disease and Related Co-Morbidities? An Overview of Available Clinical Evidence
by: Athina Dimosiari, et al.
Published: (2023-02-01)

Protective effect of anakinra on audiovestibular function in a murine model of endolymphatic hydrops
by: Na Zhang, et al.
Published: (2022-12-01)

ACO/ARO/AIO-21 - Capecitabine-based chemoradiotherapy in combination with the IL-1 receptor antagonist anakinra for rectal cancer Patients: A phase I trial of the German rectal cancer study group
by: Maximilian Fleischmann, et al.
Published: (2022-05-01)

Treating Heart Inflammation With Interleukin-1 Blockade in a Case of Erdheim–Chester Disease
by: Alessandro Tomelleri, et al.
Published: (2018-06-01)

Could anakinra outmatch dexamethasone/tocilizumab in COVID-19?
by: Rahul Gupta
Published: (2022-04-01)

The Use of Interleukine-1 Inhibitors in Familial Mediterranean Fever Patients: A Narrative Review
by: Véronique Hentgen, et al.
Published: (2020-05-01)

Investigation of the Effect of Anakinra on Pentylenetetrazole-Induced Epileptic Seizures in Mice
by: Ahmet Kemal FİLİZ, et al.
Published: (2021-08-01)

Survival and transmission of Xanthomonas oryzae pv. oryzae in rice seeds
by: Sony Mondal, et al.
Published: (2019-04-01)

OryzaGenome2.1: Database of Diverse Genotypes in Wild Oryza Species
by: Hiromi Kajiya-Kanegae, et al.
Published: (2021-03-01)

XopZ and ORP1C cooperate to regulate the virulence of Xanthomonas oryzae pv. oryzae on Nipponbare
by: Hongtao Ji, et al.
Published: (2022-12-01)

Genome editing of an African elite rice variety confers resistance against endemic and emerging Xanthomonas oryzae pv. oryzae strains
by: Van Schepler-Luu, et al.
Published: (2023-06-01)